These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38899488)
21. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients. Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465 [TBL] [Abstract][Full Text] [Related]
22. Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy. Dréau D; Bosserhoff AK; White RL; Buettner R; Holder WD Oncol Res; 1999; 11(1):55-61. PubMed ID: 10451031 [TBL] [Abstract][Full Text] [Related]
23. The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population. Li C; Liu J; Jiang L; Xu J; Ren A; Lin Y; Yao G Medicine (Baltimore); 2021 Feb; 100(8):e24840. PubMed ID: 33663104 [TBL] [Abstract][Full Text] [Related]
25. Melanoma inhibitory activity in melanoma diagnostics and therapy - a small protein is looming large. Riechers A; Bosserhoff AK Exp Dermatol; 2014 Jan; 23(1):12-4. PubMed ID: 24372647 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of multiple serum markers in advanced melanoma. Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537 [TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451 [TBL] [Abstract][Full Text] [Related]
28. The Ca Krasitskaya VV; Goncharova NS; Biriukov VV; Bashmakova EE; Kabilov MR; Baykov IK; Sokolov AE; Frank LA Photochem Photobiol; 2020 Sep; 96(5):1041-1046. PubMed ID: 32304233 [TBL] [Abstract][Full Text] [Related]
29. MIA, a novel serum marker for progression of malignant melanoma. Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221 [TBL] [Abstract][Full Text] [Related]
30. Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients. Klimek VM; Williams L; Chapman PB Cytokines Cell Mol Ther; 2002 Dec; 7(2):71-4. PubMed ID: 12607797 [TBL] [Abstract][Full Text] [Related]
31. Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing. Djukanovic D; Hofmann U; Sucker A; Schadendorf D Br J Dermatol; 2001 Dec; 145(6):1030-1. PubMed ID: 11899133 [No Abstract] [Full Text] [Related]
32. MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Müller-Ladner U; Bosserhoff AK; Dreher K; Hein R; Neidhart M; Gay S; Schölmerich J; Buettner R; Lang B Rheumatology (Oxford); 1999 Feb; 38(2):148-54. PubMed ID: 10342628 [TBL] [Abstract][Full Text] [Related]
33. Bioluminescent aptamer-based sandwich-type assay of anti-myelin basic protein autoantibodies associated with multiple sclerosis. Krasitskaya VV; Chaukina VV; Abroskina MV; Vorobyeva MA; Ilminskaya AA; Kabilov MR; Prokopenko SV; Nevinsky GA; Venyaminova AG; Frank LA Anal Chim Acta; 2019 Aug; 1064():112-118. PubMed ID: 30982509 [TBL] [Abstract][Full Text] [Related]
34. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Cao MG; Auge JM; Molina R; Martí R; Carrera C; Castel T; Vilella R; Conill C; Sánchez M; Malvehy J; Puig S Anticancer Res; 2007; 27(1B):595-9. PubMed ID: 17348447 [TBL] [Abstract][Full Text] [Related]
35. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230 [TBL] [Abstract][Full Text] [Related]
37. Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100beta or melanoma inhibitory activity (MIA)? Deichmann M; Benner A; Kuner N; Wacker J; Waldmann V; Näher H Melanoma Res; 2001 Jun; 11(3):291-6. PubMed ID: 11468518 [TBL] [Abstract][Full Text] [Related]
38. Quantification of melanoma-associated molecules in plasma/serum of melanoma patients. Hauschild A; Gläser R; Christophers E Recent Results Cancer Res; 2001; 158():169-77. PubMed ID: 11092044 [TBL] [Abstract][Full Text] [Related]
39. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma. Guba M; Steinbauer M; Ruhland V; Schütz A; Geissler EK; Anthuber M; Vogt T; Bosserhoff A; Jauch KW Oncol Rep; 2002; 9(5):981-4. PubMed ID: 12168059 [TBL] [Abstract][Full Text] [Related]
40. Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas. Wagner V; Rudi J; Näher H; Stremmel W Med Oncol; 2000 Feb; 17(1):35-8. PubMed ID: 10713658 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]